LLY vs PODD
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Insulet Corporation (PODD) presents a dichotomy between strong operational growth and a severely disconnected valuation. While the Piotroski F-Score of 4/9 indicates stable financial health and revenue growth is robust at 31.2%, the stock trades at a massive premium to its Graham Number ($41.11) and Intrinsic Value ($44.85). Despite a 'strong_buy' analyst consensus and a high target price of $333.30, the technical trend is aggressively bearish with a 36.3% decline over the last six months. The investment case relies entirely on future growth scaling and the successful international rollout of Omnipod 5 to justify the current P/E of 57.73.
Compare Another Pair
Related Comparisons
LLY vs PODD: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Insulet Corporation (PODD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.